Dr Hutson introduces the agenda for the symposium: "Optimising metastatic renal cell carcinoma (mRCC) treatment: Lessons from the real world".
Session objectives include discussing the first-line treatment options for mRCC, assessing criteria for optimising mRCC treatment, exploring how real-world experience can inform options for first-line treatment, and discussing further development in mRCC management.
This symposium has been supported by a grant from GlaxoSmithKline.